Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension Clinical Trial

— TRANSIT-1  

Official title:

Multicenter, Open-label, Single-group Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Adult Patients With Pulmonary Arterial Hypertension

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02471183
• Other study ID #: AC-065A304
• Status: Completed
• Phase: Phase 3
• First received: June 11, 2015
• Last updated: December 28, 2017
• Start date: October 12, 2015
• Est. completion date: December 5, 2016

Study information

• Verified date: December 2017
• Source: Actelion
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study enrolls patients with pulmonary arterial hypertension (PAH) treated with inhaled treprostinil. During the study, the treatment with inhaled treprostinil will be tapered off and simultaneously replaced with an oral treatment (selexipag) targeting the disease in a similar way. The purpose of the study is i) to investigate the safety and tolerability of oral selexipag in patients who transition from inhaled treprostinil, ii) to investigate the effects of oral selexipag on PAH severity and exercise ability before and after transition, and iii) to gain new information about the patients experience taking oral selexipag compared to inhaled treprostinil. Study participants may stay in the study until the FDA has granted marketing authorization.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: December 5, 2016
• Est. primary completion date: December 5, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Male and female patients aged from 18 to 75 years (inclusive) with pulmonary arterial hypertension (PAH).

• Etiology of PAH belonging to one of the following subgroups: idiopathic PAH, Heritable PAH, drug or toxin induced, associated with connective tissue disease, associated with HIV infection, associated with congenital heart disease with simple systemic-to-pulmonary shunt at least 1 year after surgical repair.

• Women of childbearing potential are eligible only if the following apply: Negative serum pregnancy test at Visit 1 and a negative urine pregnancy test at Visit on Day 1, agreement to undertake monthly urine pregnancy tests during the study and up to 30 days after study drug discontinuation, agreement to use efficient methods of birth control from Visit 1 up to at least 30 days after study treatment discontinuation.

• Documented hemodynamic diagnosis of PAH by right heart catheterization (RHC).

• Inhaled treprostinil treatment ongoing for at least 90 days and at stable dose for at least 30 days prior to Day 1.

• WHO functional class (FC) II or III at Visit 1 and Visit 2.

• 6-minute walk distance (6MWD) = 300 m at Visit 1.

• On background oral PAH therapy for at least 90 days and on a stable dose for 30 days prior to Visit 2. Acceptable concomitant PAH therapies are one or two of the following: a) Endothelin receptor antagonist (ERA), b) Phosphodiesterase type 5 (PDE-5) inhibitor or soluble guanylate cyclase (sGC) stimulator.

Exclusion Criteria:

• Treatment with any prostacyclin or prostacyclin analogs other than inhaled treprostinil within 90 days before Day 1, or patients scheduled to receive any of these treatments within the duration of the study.

• Any hospitalization within 90 days before Day 1.

• Worsening in WHO FC within 30 days prior to Day 1.

• At any time prior to Day 1, documented moderate or severe obstructive or restrictive lung disease.

• Known or suspicion of pulmonary veno-occlusive disease (PVOD).

• Anemia: < 80 g/L (5.0 mmol/L) hemoglobin.

• Clinically relevant thyroid disease (hypo- or hyperthyroidism).

• Known and documented severe hepatic impairment.

• Uncontrolled hypertension.

• Sitting systolic blood pressure < 85 mmHg.

• Acute myocardial infarction within the last 90 days prior to Visit 1.

• History of left-sided heart disease.

• Left ventricular disease/dysfunction risk factors.

• Documented pericardial effusion within 90 days prior to Visit 1.

• Documented severe renal insufficiency.

• Receiving or having received any investigational drugs within 90 days before Day 1.

• Having received selexipag at any time before Day 1.

• Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements.

• Recently conducted or planned cardio-pulmonary rehabilitation program based on exercise training during the study.

• Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements.

• Known concomitant life-threatening disease with a life expectancy < 12 months.

• Females who are lactating or pregnant or plan to become pregnant during the study.

• Known hypersensitivity to any of the excipients of the drug formulation.

Related Conditions & MeSH terms

• Familial Primary Pulmonary Hypertension
• Hypertension
• Pulmonary Arterial Hypertension

Intervention

Drug:
• Selexipag
Tablets for oral administration containing 200 micrograms (mcg) of selexipag to be administered twice a day. The individual dose is to be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).

Locations

Country	Name	City	State
United States	University of Michigan Health System	Ann Arbor	Michigan
United States	Emory University	Atlanta	Georgia
United States	Piedmont Healthcare Research Institute	Austell	Georgia
United States	UT Southwestern	Dallas	Texas
United States	Duke Unversity	Durham	North Carolina
United States	Houston Methodist Hospital	Houston	Texas
United States	UCSD Medical Center -La Jolla	La Jolla	California
United States	Kentuckiana Pulmonary Associates	Louisville	Kentucky
United States	Sentara Cardiovascular Research Instistute	Norfolk	Virginia
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	Allegheny General Hospital	Pittsburgh	Pennsylvania
United States	University of Pittsburgh Medical Center Health System	Pittsburgh	Pennsylvania
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	UCSF Medical Center	San Francisco	California
United States	Harbor UCLA Medical Center	Torrance	California

Sponsors (1)

Lead Sponsor	Collaborator
Actelion

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change From Baseline to Week 16 in the Treatment Satisfaction Questionnaire for Medication Questionnaire (TSQM II)	The Treatment Satisfaction Questionnaire for Medication, Version II (TSQM II) is a validated tool that evaluate the subject's satisfaction with the study treatment. It includes a total of 11 questions related to satisfaction with treatment effectiveness, side effects,convenience, and global satisfaction.; TSQM scores range from 0 to 100 for each domain; a higher score indicates higher satisfaction with treatment.	Baseline and Week 16
Primary	Percentage of Subjects With Sustained Treatment Transition	A sustained treatment transition is considered if the 3 following criteria are met a) being on study treatment (selexipag) at Week 16, and b) not having a study treatment interruption(s) of a total of 8 days or more prior to Week 16, and c) absence of inhaled treprostinil or any prostanoid treatment after Week 8 up to Week 16.; The percentage of subjects with a sustained treatment transition is calculated with 95% confidence interval (CI) using the Clopper-Pearson method.	At Week 16
Primary	Percentage of Subjects With Treatment-emergent Adverse Events (AEs),	Percentage of subjects with treatment-emergent AEs (serious and non serious), regardless of relationship to selexipag	26 weeks on average (from the first dose of selexipag up to 30 days after the last dose of selexipag)
Primary	Number of Subjects With Adverse Events Leading to Premature Discontinuation of Selexipag	Number of subjects with adverse events leading to premature discontinuation of selexipag is determined from the first dose of selexipag up to the last dose of selexipag	Up to 22 weeks on average
Primary	Absolute Change From Baseline Over Time in Blood Pressure	Both systolic(SBP) and diastolic (DBP) arterial blood pressure were measured in a sitting position after at least 5 minutes of rest at scheduled time points. Median change from baseline to pre-specified post-baseline visits are calculated	Baseline, Week 4, Week 12, Week 16
Primary	Absolute Change From Baseline Over Time in Heart Rate (HR)	Pulse rate is measured after at least 5 minutes of rest in a sitting position. Median change from baseline to pre-specified post-baseline visits are calculated.	Baseline, Week 4, Week 12, Week 16
Primary	Maximal Tolerated Dose	This is the individual maximal tolerated dose (MTD) observed at Week 12 in the subjects still on selexipag at Week 16.; MTD is defined as the dose of selexipag reached with the last dose change up to Week 12	At Week 12, in subjects still on selexipag at Week 16
Primary	Time to Discontinuation of Inhaled Treprostinil.	Median time from baseline (Day1) to the end of down-titration of inhaled treprostinil is calculated	Baseline to Week 16
Secondary	Percentage of Subjects With WHO Functional Class (FC) Change From Baseline	The World Health Organization (WHO) defines 4 classes to classify the functional status of patients with pulmonary hypertension: Class I (FC I): No limitation of physical activity. Class II (FC II): Slight limitation of physical activity. Class III (FC III): Marked limitation of physical activity. Class IV (FC IV): Inability to carry out any physical activity without symptoms.; Number of patients with improvement (shift from a higher to a lower class), worsening (shift from a lower to a higher class) or no change in WHO functional class at end of study compared to baseline are determined.	Baseline and Week 16
Secondary	Absolute Change in 6-minute Walk Distance (6MWD) at Trough	The 6MWT is a non-encouraged test, which measures the distance (in meters) covered by the subject during a 6-minute walk. It is performed in a 30-meters long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed.; Absolute change from baseline to Week 16 in 6MWD is measured at trough levels of inhaled treprostinil and/or selexipag. The trough level of inhaled treprostinil is defined as the last dose having been taken not less than 4 hours and not more than 48 hours prior to the 6MWT at Visit 1 (screening). The trough level of selexipag was defined as the last dose having been taken not less than 8 hours and not more than 7 days prior to the 6MWT at Visit 5 (Week 16).	Baseline and Week 16
Secondary	Percentage of Patients With Change in 6-minute Walk Distance (6MWD)	Percentage of patients with an increase (> 8% of baseline), maintenance (+/- 8% of baseline), or decrease (< -8% of baseline) in their 6MWD (at trough) from baseline to Week 16. The ± 8% boundaries for change in 6MWD reflect the approximately 8% coefficient of variation in the reproducibility of the 6MWD.; The trough level of inhaled treprostinil is defined as the last dose having been taken not less than 4 hours and not more than 48 hours prior to the 6MWD test at Visit 1 (screening). The trough level of selexipag was defined as the last dose having been taken not less than 8 hours and not more than 7 days prior to the 6MWD test at Visit 5 (Week 16).	Baseline and Week 16
Secondary	Geometric Mean of the Ratio in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) of Week 16 to Baseline	Changes in NT-proBNP levels in plasma are expressed by the geometric mean of the ratio of Week 16 to baseline	Baseline and Week 16